Argenx SE (NASDAQ:ARGX) ranks among the most profitable biotech stocks to buy now. On April 14, TD Cowen maintained its Buy rating and $1,146 price target for Argenx SE (NASDAQ:ARGX), citing a quarterly monitoring poll that indicated first-quarter sales could outperform consensus projections. The firm’s fifth quarterly study of 30 neurologists treating patients with generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy revealed persistent interest in the Vyvgart brand.
According to TD Cowen, Vyvgart’s first-quarter revenues will exceed the consensus expectation of $1,271 million, which is a 1% decrease from the previous quarter. The firm ascribed the predicted increase to the adoption of the Vyvgart Hytrulo prefilled syringe formulation.
According to the aforesaid study, the prefilled syringe formulation, which is still being used in both generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy diagnosis, was notably favored.
TD Cowen also voiced optimism about possible launches in ocular myasthenia gravis, for which a submission is expected shortly, and seronegative myasthenia gravis, which has a regulatory judgment date of May 10.
Argenx SE (NASDAQ:ARGX) is a biotech company that develops treatments for severe autoimmune diseases. The company operates through four segments: the United States, Japan, EMEA, and China.
While we acknowledge the potential of ARGX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
Disclosure: None. Follow Insider Monkey on Google News.
finance.yahoo.com
#Argenx #ARGX #Outlook #Improves #Autoimmune #Pipeline #Expansion
